FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1666305429> ?p ?o ?g. }

• W1666305429 abstract "Background Functional immaturity of gastrointestinal motility predisposes preterm infants to feeding intolerance. Erythromycin is a motilin agonist that exerts its prokinetic effect by stimulating propagative contractile activity in the interdigestive phase. Objectives To evaluate the efficacy of erythromycin in the prevention and treatment of feeding intolerance in preterm infants. Search methods Systematic literature search was performed according to the Cochrane Neonatal Collaborative Review Group search strategy. Randomized controlled trials of erythromycin in preterm infants to promote gastrointestinal motility were identified from the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 4, 2007), MEDLINE (1966 ‐ December 2007), EMBASE (1980 ‐ December 2007), CINAHL (1982 ‐ December 2007), cross‐references, abstracts, and journal hand searching. Selection criteria The initial selection criteria limited the review to studies using erythromycin at 3 ‐ 12 mg/kg/day in preterm infants less than 36 weeks gestational age with feeding tolerance. However, a significant number of studies using erythromycin at a higher dose (> 12 mg/kg/day) or as prophylaxis for those at risk of feeding intolerance were identified. A post hoc decision was made to include these studies in the review. Data collection and analysis Studies were categorized into prevention and treatment studies, and data from each category were analyzed separately. Within each category, subgroup analyses were performed based on low (3 to 12mg/kg/day) and high doses (> 12mg/kg/day) of erythromycin. Primary outcome was days to full enteral feeding. Secondary outcomes included adverse effects associated with erythromycin, duration of total parenteral nutrition (TPN), weight gain, necrotizing enterocolitis (NEC), and length of hospital stay. Main results Ten randomized controlled studies (three prevention and seven treatment studies) were included. Studies varied greatly in the definition of feeding intolerance and how outcomes were measured, analyzed and reported, so meta‐analysis of most outcomes was impossible. It was observed, however, that the studies using erythromycin at higher treatment doses (40 to 50 mg/kg/day) or in infants > 32 weeks' GA reported more positive effects in improving feeding intolerance. Meta‐analysis of high dose prevention studies showed no significant difference in NEC (typical RR 0.59, 95% CI 0.11, 3.01; typical RD ‐0.021, 95% CI ‐0.087, 0.045). Meta‐analysis of high dose treatment studies showed no significant difference in septicemia (typical RR 0.83, 95% CI 0.47, 1.45; typical RD ‐0.04, 95% CI ‐0.17, 0.08). Authors' conclusions There is insufficient evidence to recommend the use of erythromycin in low or high doses for preterm infants with or at risk of feeding intolerance. Future research is needed to determine if there is a more precise dose range where erythromycin might be effective as a prokinetic agent in preterm infants > 32 weeks' GA." @default.
• W1666305429 created "2016-06-24" @default.
• W1666305429 creator A5005945324 @default.
• W1666305429 creator A5016581171 @default.
• W1666305429 date "2008-07-16" @default.
• W1666305429 modified "2023-10-06" @default.
• W1666305429 title "Erythromycin for the prevention and treatment of feeding intolerance in preterm infants" @default.
• W1666305429 cites W1480500461 @default.
• W1666305429 cites W1490064049 @default.
• W1666305429 cites W1494325917 @default.
• W1666305429 cites W1761976336 @default.
• W1666305429 cites W1767843666 @default.
• W1666305429 cites W1987714567 @default.
• W1666305429 cites W1989521095 @default.
• W1666305429 cites W1991320940 @default.
• W1666305429 cites W2000708217 @default.
• W1666305429 cites W2002736982 @default.
• W1666305429 cites W2004765164 @default.
• W1666305429 cites W2007103673 @default.
• W1666305429 cites W2013220252 @default.
• W1666305429 cites W2036033411 @default.
• W1666305429 cites W2040070604 @default.
• W1666305429 cites W2046821842 @default.
• W1666305429 cites W2061604286 @default.
• W1666305429 cites W2084248346 @default.
• W1666305429 cites W2094671035 @default.
• W1666305429 cites W2105231848 @default.
• W1666305429 cites W2108232795 @default.
• W1666305429 cites W2133356829 @default.
• W1666305429 cites W2143763896 @default.
• W1666305429 cites W2144319263 @default.
• W1666305429 cites W2150172787 @default.
• W1666305429 cites W2155626591 @default.
• W1666305429 cites W2156615086 @default.
• W1666305429 cites W2164022933 @default.
• W1666305429 cites W2171877085 @default.
• W1666305429 cites W2321937552 @default.
• W1666305429 cites W2328097473 @default.
• W1666305429 cites W91386120 @default.
• W1666305429 doi "https://doi.org/10.1002/14651858.cd001815.pub2" @default.
• W1666305429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18646077" @default.
• W1666305429 hasPublicationYear "2008" @default.
• W1666305429 type Work @default.
• W1666305429 sameAs 1666305429 @default.
• W1666305429 citedByCount "29" @default.
• W1666305429 countsByYear W16663054292012 @default.
• W1666305429 countsByYear W16663054292013 @default.
• W1666305429 countsByYear W16663054292014 @default.
• W1666305429 countsByYear W16663054292015 @default.
• W1666305429 countsByYear W16663054292016 @default.
• W1666305429 countsByYear W16663054292017 @default.
• W1666305429 countsByYear W16663054292018 @default.
• W1666305429 countsByYear W16663054292019 @default.
• W1666305429 countsByYear W16663054292020 @default.
• W1666305429 countsByYear W16663054292021 @default.
• W1666305429 countsByYear W16663054292023 @default.
• W1666305429 crossrefType "journal-article" @default.
• W1666305429 hasAuthorship W1666305429A5005945324 @default.
• W1666305429 hasAuthorship W1666305429A5016581171 @default.
• W1666305429 hasConcept C126322002 @default.
• W1666305429 hasConcept C168563851 @default.
• W1666305429 hasConcept C187212893 @default.
• W1666305429 hasConcept C197934379 @default.
• W1666305429 hasConcept C2776478404 @default.
• W1666305429 hasConcept C2778376644 @default.
• W1666305429 hasConcept C2779083892 @default.
• W1666305429 hasConcept C2779234561 @default.
• W1666305429 hasConcept C2779303187 @default.
• W1666305429 hasConcept C2780206985 @default.
• W1666305429 hasConcept C44315111 @default.
• W1666305429 hasConcept C501593827 @default.
• W1666305429 hasConcept C54355233 @default.
• W1666305429 hasConcept C71924100 @default.
• W1666305429 hasConcept C78722104 @default.
• W1666305429 hasConcept C86803240 @default.
• W1666305429 hasConcept C89423630 @default.
• W1666305429 hasConceptScore W1666305429C126322002 @default.
• W1666305429 hasConceptScore W1666305429C168563851 @default.
• W1666305429 hasConceptScore W1666305429C187212893 @default.
• W1666305429 hasConceptScore W1666305429C197934379 @default.
• W1666305429 hasConceptScore W1666305429C2776478404 @default.
• W1666305429 hasConceptScore W1666305429C2778376644 @default.
• W1666305429 hasConceptScore W1666305429C2779083892 @default.
• W1666305429 hasConceptScore W1666305429C2779234561 @default.
• W1666305429 hasConceptScore W1666305429C2779303187 @default.
• W1666305429 hasConceptScore W1666305429C2780206985 @default.
• W1666305429 hasConceptScore W1666305429C44315111 @default.
• W1666305429 hasConceptScore W1666305429C501593827 @default.
• W1666305429 hasConceptScore W1666305429C54355233 @default.
• W1666305429 hasConceptScore W1666305429C71924100 @default.
• W1666305429 hasConceptScore W1666305429C78722104 @default.
• W1666305429 hasConceptScore W1666305429C86803240 @default.
• W1666305429 hasConceptScore W1666305429C89423630 @default.
• W1666305429 hasLocation W16663054291 @default.
• W1666305429 hasLocation W16663054292 @default.
• W1666305429 hasOpenAccess W1666305429 @default.
• W1666305429 hasPrimaryLocation W16663054291 @default.
• W1666305429 hasRelatedWork W2001347519 @default.
• W1666305429 hasRelatedWork W2014260342 @default.
• W1666305429 hasRelatedWork W2094385255 @default.

• next